Skip to content
November 15, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Treatment Innovations
  • Advancing Federal Diagnostics: MellingMedical and CellTivity Scientific Forge Strategic Alliance for Cancer Imaging
  • Treatment Innovations

Advancing Federal Diagnostics: MellingMedical and CellTivity Scientific Forge Strategic Alliance for Cancer Imaging

Nana November 15, 2026 7 minutes read
advancing-federal-diagnostics-mellingmedical-and-celltivity-scientific-forge-strategic-alliance-for-cancer-imaging

In a move set to transform diagnostic capabilities across the United States federal healthcare landscape, MellingMedical has announced a strategic partnership with CellTivity Scientific. This collaboration marks a significant milestone in medical technology distribution, focused on bringing the cutting-edge Van Gogh Microscopy System—an FDA-classified Class I in vitro diagnostic (IVD) device—to the front lines of care for active-duty military personnel, veterans, and their families.

The Core Innovation: Redefining Tissue Analysis

At the heart of this partnership is the Van Gogh Microscopy System, a platform that utilizes proprietary Dynamic Cell Imaging (DCI) technology. Unlike traditional histopathology, which often requires invasive tissue processing—including fixing, cutting, and staining—the Van Gogh system provides a non-destructive alternative.

By leveraging DCI, the system allows clinicians to examine freshly excised biopsy specimens in real-time. It achieves this by digitally recording metabolic and intracellular activity up to 150µm beneath the tissue surface. Because this optical assessment bypasses the need for physical manipulation, 100% of the sample remains entirely intact. This preservation is critical, as it ensures that the specimen remains available for subsequent molecular analysis, such as next-generation sequencing (NGS), and formal gold-standard pathology.

For federal healthcare providers, the implications are profound. By providing an immediate, high-resolution look at metabolic activity at the point of care, the Van Gogh system serves as a powerful tool to guide intraprocedural tissue sampling. This reduces the risk of “non-diagnostic” biopsies, mitigating delays in diagnosis and curbing the diagnostic inaccuracies that can occur when tissue quality is compromised during initial processing.

A Chronology of Integration: Scaling Advanced Diagnostics

The integration of the Van Gogh system into the federal network is the result of a deliberate, multi-layered strategic effort. While the technology has been moving through the regulatory and validation pathways of the FDA, the finalization of this distribution agreement represents the culmination of efforts to bridge the gap between innovation and clinical application.

Phase 1: Regulatory Validation

The journey began with the rigorous assessment of the Van Gogh system under FDA guidelines. Achieving Class I IVD status served as the foundational prerequisite, confirming the safety and reliability of the device for clinical use.

Phase 2: Strategic Network Alignment

CellTivity Scientific sought a partner capable of navigating the complex procurement infrastructure of the US federal government. MellingMedical, a Service-Disabled Veteran-Owned Small Business (SDVOSB), was selected due to its established track record and extensive contracting reach.

Phase 3: Deployment Strategy

With the partnership formalized, the focus has shifted to the deployment of the hardware across the vast network of the Department of Defense (DoD) and the Department of Veterans Affairs (VA). The rollout is designed to prioritize facilities where rapid, high-accuracy diagnostic turnaround is most critical for patient outcomes, particularly in oncology and surgical oncology settings.

Supporting Data: The Power of the MellingMedical Network

The efficiency of this partnership relies on MellingMedical’s unique position within the federal supply chain. As an SBA-verified SDVOSB, the company holds critical vehicles, including the Medical Equipment and Surgical Federal Supply Schedule (Med/Surg), a Pharmaceutical Schedule, and extensive electronic catalogue (ECAT) capabilities.

This infrastructure is not merely administrative; it is a massive logistical engine that reaches:

  • Department of Defense: Over 95 military medical facilities.
  • Veterans Affairs: 172 VA Medical Centers and more than 1,138 VA Outpatient Clinics.
  • Specialized Care: Seven VA Consolidated Mail Outpatient Pharmacies (VA CMOPs).
  • Public Health Infrastructure: Coverage extending to the Department of Health and Human Services (HHS), including the Centers for Disease Control and Prevention (CDC) and the Indian Health Service (IHS).

This distribution reach ensures that the Van Gogh Microscopy System will not be limited to high-level research hospitals but will instead be accessible in clinical settings that serve a broad spectrum of the veteran population.

MellingMedical and CellTivity agree federal diagnostic supply deal

Official Perspectives: Aligning Vision and Execution

The leadership of both organizations has expressed strong confidence in the synergy created by this alliance. For Chris Melling, founder and CEO of MellingMedical, the partnership is a direct fulfillment of his company’s mission to provide “best-in-class” technology to those who have served the nation.

"CellTivity’s track record of engineering high-quality, innovative diagnostic workflow solutions makes them an ideal ally for serving federal healthcare providers," Melling stated during the announcement. "Their specialized focus on cutting-edge technologies like the Van Gogh system will provide federal healthcare clinicians with the tools they need to enhance diagnostic confidence, maximize tissue sufficiency for next-generation sequencing, and deliver timely, optimal patient care."

From the perspective of CellTivity Scientific, the partnership acts as a force multiplier. By leveraging MellingMedical’s existing relationships, CellTivity can bypass the arduous process of establishing individual contracts with hundreds of facilities, allowing them to focus on training, support, and the technical evolution of the Van Gogh platform.

Implications for the Future of Federal Healthcare

The introduction of the Van Gogh system into the VA and DoD networks signals a broader shift toward "precision diagnostics" within the public sector.

1. The End of "Guesswork" in Biopsies

One of the most persistent challenges in oncology is the "non-representative sample." If a biopsy is taken from an area of tissue that is metabolically inactive, the resulting diagnosis may be inaccurate. The Van Gogh system’s ability to map metabolic activity before the specimen is fully removed allows surgeons and oncologists to pinpoint the most active sites of disease, ensuring the sample is biologically meaningful.

2. Streamlining the Diagnostic Workflow

Current pathology workflows are often bottlenecked by the physical processing of tissue. By providing real-time data, the Van Gogh system allows for "intraprocedural" decision-making. If a clinician can confirm the presence of malignant cells while the patient is still on the table, the need for repeat procedures is drastically reduced. This saves time, reduces anesthesia exposure for the patient, and lowers the overall cost per case for the healthcare system.

3. Preserving Tissue for the Genomic Era

As medicine moves toward personalized, molecularly-driven treatments, the need for high-quality tissue is greater than ever. Next-generation sequencing (NGS) requires a specific amount of high-quality, preserved genetic material. Traditional biopsy methods can sometimes damage the DNA or RNA within a sample due to the chemicals used in staining or the heat generated during processing. Because the Van Gogh system is non-destructive, it provides a perfect, pristine sample for the downstream genomic testing that informs modern immunotherapy and targeted cancer treatments.

4. Supporting the Veteran Experience

For veterans and active-duty personnel, who often rely on a centralized system for their comprehensive healthcare, this technology represents a significant upgrade in the quality of care. Faster diagnosis leads to shorter wait times for treatment initiation, which is the most critical variable in cancer prognosis. By placing the Van Gogh system into VA centers across the country, the government is effectively democratizing access to state-of-the-art diagnostic technology.

Conclusion

The partnership between MellingMedical and CellTivity Scientific is more than a commercial agreement; it is an infrastructure investment in the future of federal medicine. By combining the logistical prowess of a veteran-focused distributor with the high-tech precision of Dynamic Cell Imaging, the federal government is positioning its healthcare network to lead in the diagnostic space.

As the Van Gogh Microscopy System is deployed across the DoD and VA, the healthcare community will be watching closely. If the system performs as expected, it could set a new standard for diagnostic workflow in oncology, turning the "wait and see" model into a "see and act" reality. For the millions of Americans who depend on the federal healthcare system, this shift promises not just better diagnostics, but better outcomes, shorter wait times, and a higher standard of care for those who have sacrificed the most.

About the Author

Nana

Author

View All Posts

Post navigation

Previous: Shaping the Future of Therapeutics: A Deep Dive into AAPS PharmSci 360 2026

Related Stories

shaping-the-future-of-therapeutics-a-deep-dive-into-aaps-pharmsci-360-2026
  • Treatment Innovations

Shaping the Future of Therapeutics: A Deep Dive into AAPS PharmSci 360 2026

Jia Lissa November 15, 2026
arga-medtech-hits-major-milestone-in-pivotal-coherent-af-trial-for-pulsed-field-ablation-technology
  • Treatment Innovations

Argá Medtech Hits Major Milestone in Pivotal COHERENT-AF Trial for Pulsed-Field Ablation Technology

Nana Wu November 15, 2026
aaps-appoints-academic-and-industry-luminary-dr-patrick-j-sinko-as-chief-science-officer
  • Treatment Innovations

AAPS Appoints Academic and Industry Luminary Dr. Patrick J. Sinko as Chief Science Officer

Iffa Jayyana November 15, 2026

Recent Posts

  • Advancing Federal Diagnostics: MellingMedical and CellTivity Scientific Forge Strategic Alliance for Cancer Imaging
  • Shaping the Future of Therapeutics: A Deep Dive into AAPS PharmSci 360 2026
  • The Genetic Architecture of Resilience: Largest International Twin Study Decodes Why We Respond Differently to Life’s Challenges
  • The Art of Intentional Giving: 10 Curated Wellness Tools for the Mindful Modernist
  • Resilience, Legacy, and the Art of the Present: The Story of Mark and Shanti

Recent Comments

No comments to show.

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

advancing-federal-diagnostics-mellingmedical-and-celltivity-scientific-forge-strategic-alliance-for-cancer-imaging
  • Treatment Innovations

Advancing Federal Diagnostics: MellingMedical and CellTivity Scientific Forge Strategic Alliance for Cancer Imaging

Nana November 15, 2026
shaping-the-future-of-therapeutics-a-deep-dive-into-aaps-pharmsci-360-2026
  • Treatment Innovations

Shaping the Future of Therapeutics: A Deep Dive into AAPS PharmSci 360 2026

Jia Lissa November 15, 2026
Legs, toes, feet and heels of newborn twins. Wrapped in a knitted white blanket. Studio macro photography of the legs of newborn twins, close-up white backgraund. Two newborns.
  • Genomics and Precision Medicine

The Genetic Architecture of Resilience: Largest International Twin Study Decodes Why We Respond Differently to Life’s Challenges

Basiran November 15, 2026
the-art-of-intentional-giving-10-curated-wellness-tools-for-the-mindful-modernist
  • Integrative Oncology and Holistic Care

The Art of Intentional Giving: 10 Curated Wellness Tools for the Mindful Modernist

Jia Lissa November 15, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.